@Article{info:doi/10.2196/39012,
author="Lima, Souza Vivian Cristina Gama
and Soares, Souza Raquel de
and Santos, dos Willian Alves
and Alves, Paulo
and Fuly, Claro Patricia dos Santos",
title="Scientific Publications on Nursing for COVID-19 in Patients With Cancer: Scoping Review",
journal="JMIR Cancer",
year="2022",
month="Nov",
day="25",
volume="8",
number="4",
pages="e39012",
keywords="COVID-19",
keywords="review",
keywords="nursing",
keywords="coronavirus infection",
keywords="oncology nursing",
abstract="Background: The needs of patients with cancer must be met, especially in times of crisis. The advent of the pandemic triggered a series of strategic actions by the nursing team to preserve the health of patients and professionals---hence the importance of studies on nursing care actions provided to patients with cancer during the COVID-19 pandemic. It is known that these patients are susceptible to severe COVID-19. However, no previous review has summarized the findings of scientific studies on nursing for COVID-19 in patients with cancer. Objective: This study aims to map the topics addressed in scientific studies on nursing for COVID-19 in patients with cancer. Methods: A scoping review was conducted using the methodology described in the Joanna Briggs Institute Reviewers' Manual 2015. The research question was elaborated using the population, concept, and context framework: What topics have been studied in nursing publications about COVID-19 in adult patients with cancer? The searches were carried out in 8 databases between April and November 2021 without time restrictions. Results: In total, 973 publications were identified using the search strategies in the databases, and 12 papers were retrieved by consulting the references. A total of 31 (3.2\%) publications were included in the final analysis, generating 4 thematic categories on the subject: ``restructuring the services: how oncology nursing was adapted during the pandemic,'' ``experiences of patients and performance of the nursing team during the COVID-19 pandemic,'' ``protocols and recommendations for dealing with the COVID-19 pandemic,'' and ``challenges and the role of oncology nurses facing the COVID-19 pandemic.'' Conclusions: Several strategies used by oncology nurses to face the COVID-19 pandemic in the international scenario were identified. Reports about the restructuring of services and the team's reactions to the pandemic predominated. However, there is a lack of reports regarding emotional support strategies for health care professionals. Another gap identified was the scarcity of clinical studies on the activities developed by oncology nurses. Therefore, there is a need for clinical research in the oncology area and emotional coping strategies to support oncology nurses. ",
doi="10.2196/39012",
url="https://cancer.jmir.org/2022/4/e39012",
url="http://www.ncbi.nlm.nih.gov/pubmed/36219752"
}


@Article{info:doi/10.2196/38088,
author="Ankersmid, Wies Jet
and Siesling, Sabine
and Strobbe, A. Luc J.
and Meulepas, M. Johanna
and van Riet, A. Yvonne E.
and Engels, Noel
and Prick, M. Janine C.
and The, Regina
and Takahashi, Asako
and Velting, Mirjam
and van Uden-Kraan, F. Cornelia
and Drossaert, C. Constance H.",
title="Supporting Shared Decision-making About Surveillance After Breast Cancer With Personalized Recurrence Risk Calculations: Development of a Patient Decision Aid Using the International Patient Decision AIDS Standards Development Process in Combination With a Mixed Methods Design",
journal="JMIR Cancer",
year="2022",
month="Nov",
day="14",
volume="8",
number="4",
pages="e38088",
keywords="patient decision aid",
keywords="PtDA",
keywords="breast cancer",
keywords="surveillance",
keywords="risk information",
keywords="shared decision-making",
keywords="SDM",
abstract="Background: Although the treatment for breast cancer is highly personalized, posttreatment surveillance remains one-size-fits-all: annual imaging and physical examination for at least five years after treatment. The INFLUENCE nomogram is a prognostic model for estimating the 5-year risk for locoregional recurrences and second primary tumors after breast cancer. The use of personalized outcome data (such as risks for recurrences) can enrich the process of shared decision-making (SDM) for personalized surveillance after breast cancer. Objective: This study aimed to develop a patient decision aid (PtDA), integrating personalized risk calculations on risks for recurrences, to support SDM for personalized surveillance after curative treatment for invasive breast cancer. Methods: For the development of the PtDA, the International Patient Decision Aids Standards development process was combined with a mixed methods design inspired by the development process of previously developed PtDAs. In the development, 8 steps were distinguished: establishing a multidisciplinary steering group; definition of the end users, scope, and purpose of the PtDA; assessment of the decisional needs of end users; defining requirements for the PtDA; determining the format and implementation strategy for the PtDA; prototyping; alpha testing; and beta testing. The composed steering group convened during regular working-group sessions throughout the development process. Results: The ``Breast Cancer Surveillance Decision Aid'' consists of 3 components that support the SDM process: a handout sheet on which personalized risks for recurrences, calculated using the INFLUENCE-nomogram, can be visualized and which contains an explanation about the decision for surveillance and a login code for a web-based deliberation tool; a web-based deliberation tool, including a patient-reported outcome measure on fear of cancer recurrence; and a summary sheet summarizing patient preferences and considerations. The PtDA was assessed as usable and acceptable during alpha testing. Beta testing is currently ongoing. Conclusions: We developed an acceptable and usable PtDA that integrates personalized risk calculations for the risk for recurrences to support SDM for surveillance after breast cancer. The implementation and effects of the use of the ``Breast Cancer Surveillance Decision Aid'' are being investigated in a clinical trial. ",
doi="10.2196/38088",
url="https://cancer.jmir.org/2022/4/e38088",
url="http://www.ncbi.nlm.nih.gov/pubmed/36374536"
}


@Article{info:doi/10.2196/39271,
author="Skiba, B. Meghan
and Harker, Graham
and Guidarelli, Carolyn
and El-Gohary, Mahmoud
and Horak, Fay
and Roeland, J. Eric
and Silbermann, Rebecca
and Hayes-Lattin, Brandon
and Winters-Stone, Kerri",
title="Using Wearable Inertial Sensors to Assess Mobility of Patients With Hematologic Cancer and Associations With Chemotherapy-Related Symptoms Before Autologous Hematopoietic Stem Cell Transplant: Cross-sectional Study",
journal="JMIR Cancer",
year="2022",
month="Dec",
day="8",
volume="8",
number="4",
pages="e39271",
keywords="wearable inertial sensor",
keywords="mobility",
keywords="gait",
keywords="induction chemotherapy",
keywords="autologous hematopoietic stem cell transplant",
keywords="autoHSCT",
keywords="chemotherapy-related symptoms",
abstract="Background: Wearable sensors could be a simple way to quantify and characterize mobility in patients with hematologic cancer scheduled to receive autologous hematopoietic stem cell transplant (autoHSCT) and how they may be related to common treatment-related symptoms and side effects of induction chemotherapy. Objective: We aimed to conduct a cross-sectional study comparing mobility in patients scheduled to receive autoHSCT with that in healthy, age-matched adult controls and determine the relationships between patient mobility and chemotherapy-related symptoms. Methods: Patients scheduled to receive autoHSCT (78/156, 50\%) and controls (78/156, 50\%) completed the prescribed performance tests using wearable inertial sensors to quantify mobility including turning (turn duration and number of steps), gait (gait speed, stride time, stride time variability, double support time, coronal trunk range of motion, heel strike angle, and distance traveled), and balance (coronal sway, coronal range, coronal velocity, coronal centroidal frequency, sagittal sway, sagittal range, sagittal velocity, and sagittal centroidal frequency). Patients completed the validated patient-reported questionnaires to assess symptoms common to chemotherapy: chemotherapy-induced peripheral neuropathy (Functional Assessment of Cancer Therapy/Gynecologic Oncology Group--Neurotoxicity subscale), nausea and pain (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire), fatigue (Patient-Reported Outcomes Measurement Information System Fatigue Short Form 8a), vertigo (Vertigo Symptom Scale--short form), and depression (Center for Epidemiological Studies--Depression). Paired, 2-sided t tests were used to compare mobility between patients and controls. Stepwise multivariable linear regression models were used to evaluate associations between patient mobility and symptoms. Results: Patients aged 60.3 (SD 10.3) years had significantly worse turning (turn duration; P<.001), gait (gait speed, stride time, stride time variability, double support time, heel strike angle, stride length, and distance traveled; all P<.001), and balance (coronal sway; P<.001, range; P<.001, velocity; P=.02, and frequency; P=.02; and sagittal range; P=.008) than controls. In patients, high nausea was associated with worse stride time variability ({\ss}=.001; P=.005) and heel strike angle ({\ss}=?.088; P=.02). Pain was associated with worse gait speed ({\ss}=?.003; P=.003), stride time variability ({\ss}=.012; P=.02), stride length ({\ss}=?.002; P=.004), and distance traveled ({\ss}=?.786; P=.005). Nausea and pain explained 17\% to 33\% and 14\% to 36\% of gait variance measured in patients, respectively. Conclusions: Patients scheduled to receive autoHSCT demonstrated worse mobility in multiple turning, gait, and balance domains compared with controls, potentially related in part to nausea and pain. Wearable inertial sensors used in the clinic setting could provide granular information about mobility before further treatment, which may in turn benefit from rehabilitation or symptom management. Future longitudinal studies are needed to better understand temporal changes in mobility and symptoms across the treatment trajectory to optimally time, design, and implement strategies, to preserve functioning in patients with hematologic cancer in the long term. ",
doi="10.2196/39271",
url="https://cancer.jmir.org/2022/4/e39271",
url="http://www.ncbi.nlm.nih.gov/pubmed/36480243"
}


@Article{info:doi/10.2196/40600,
author="Akahane, Takemi
and Nakanishi, Yasuhiro
and Yoshiji, Hitoshi
and Akahane, Manabu",
title="Esophagogastroduodenoscopy Screening Intentions During the COVID-19 Pandemic in Japan: Web-Based Survey",
journal="JMIR Cancer",
year="2022",
month="Nov",
day="11",
volume="8",
number="4",
pages="e40600",
keywords="COVID-19",
keywords="cancer screening",
keywords="esophagogastroduodenoscopy",
keywords="EGD",
keywords="intention",
keywords="survey",
keywords="cancer",
keywords="Japan",
keywords="screening",
keywords="men",
keywords="women",
keywords="anxiety",
keywords="information",
keywords="infection",
abstract="Background: The number of people undergoing cancer screening decreased during the COVID-19 pandemic. The pandemic may have affected the willingness and motivation of undergoing cancer screening by those eligible for it. Objective: This study aims to clarify the effect of the COVID-19 pandemic on the intention to undergo cancer and esophagogastroduodenoscopy (EGD) screening. Methods: We performed a web-based survey on the intention to undergo screening among 1236 men and women aged 20-79 years. The numbers of participants by sex and 10-year age groups were equal. The survey was conducted in January 2021, during which the government declared a state of emergency because of the third wave of the COVID-19 pandemic in Japan. Emergency declarations were issued in 11 prefectures among all the 47 prefectures in Japan. Results: In total, 66.1\% (817/1236) of the participants felt anxious about undergoing screening due to COVID-19. More women than men were anxious about undergoing screening. By modality, EGD had the highest percentage of participants with anxiety due to COVID-19. Regarding the intention to change the participants' appointment for screening, the most common strategies were to book an appointment for a time during nonpeak hours, postpone the appointment to a later date, and change the mode of transportation. In addition, 35.8\% (442/1236) of the participants were willing to cancel this year's screening appointment. Among the 1236 participants, 757 (61.2\%) were scheduled for screening in 2020. Of the 757 participants in this subgroup, 68\% (n=515) did not change the schedule, 6.1\% (n=46) cancelled, and 26\% (n=197) made some changes, including changing the appointment date, hospital, or mode of transportation. Among the 296 participants scheduled for EGD screening, 18.9\% (n=56) made some changes, 5.7\% (n=17) cancelled on their own, and 2.7\% (n=8) cancelled on the hospital's order. Based on the previous screening results, the percentage of participants who felt anxious about EGD due to the COVID-19 pandemic was higher in the order of those who had not undergone screening and those who were judged to be in need of further examination in screening but did not visit a hospital for it. In the logistic regression analysis, the factors associated with anxiety about EGD screening due to the COVID-19 pandemic were ``viral infection prevention measures,'' ``waiting time,'' ``fees (medical expenses),'' ``mode of transportation,'' ``worry about my social position if I contracted COVID-19,'' and ``perceived the risk of gastric cancer.'' However, ``residence in declared emergency area'' was not associated with EGD anxiety due to COVID-19. Conclusions: Excessive anxiety about COVID-19 may lead to serious outcomes, such as a ``decreasing intention to undergo EGD screening,'' and it is necessary to thoroughly implement infection prevention measures and provide correct information to examinees. ",
doi="10.2196/40600",
url="https://cancer.jmir.org/2022/4/e40600",
url="http://www.ncbi.nlm.nih.gov/pubmed/36343187"
}


@Article{info:doi/10.2196/39725,
author="Conduit, Ciara
and Guo, Christina
and Smith, B. Allan
and Rincones, Orlando
and Baenziger, Olivia
and Thomas, Benjamin
and Goad, Jeremy
and Lenaghan, Dan
and Lawrentschuk, Nathan
and Wong, Lih-Ming
and Corcoran, M. Niall
and Ross, Margaret
and Gibbs, Peter
and O'Haire, Sophie
and Anton, Angelyn
and Liow, Elizabeth
and Lewin, Jeremy
and Tran, Ben",
title="Role for a Web-Based Intervention to Alleviate Distress in People With Newly Diagnosed Testicular Cancer: Mixed Methods Study",
journal="JMIR Cancer",
year="2022",
month="Oct",
day="28",
volume="8",
number="4",
pages="e39725",
keywords="testicular germ cell tumor",
keywords="cancer survivors",
keywords="emotional distress",
keywords="anxiety disorders",
keywords="depression",
abstract="Background: Distress is common immediately after diagnosis of testicular cancer. It has historically been difficult to engage people in care models to alleviate distress because of complex factors, including differential coping strategies and influences of social gender norms. Existing support specifically focuses on long-term survivors of testicular cancer, leaving an unmet need for age-appropriate and sex-sensitized support for individuals with distress shortly after diagnosis. Objective: We evaluated a web-based intervention, Nuts \& Bolts, designed to provide support and alleviate distress after diagnosis of testicular cancer. Methods: Using a mixed methods design to evaluate the acceptability, feasibility, and impact of Nuts \& Bolts on distress, we randomly assigned participants with recently diagnosed testicular cancer (1:1) access to Nuts \& Bolts at the time of consent (early) or alternatively, 1 week later (day 8; delayed). Participants completed serial questionnaires across a 4- to 5-week period to evaluate levels of distress (measured by the National Comprehensive Cancer Network Distress Thermometer [DT]; scored 0-10), anxiety, and depression (Hospital Anxiety and Depression Score [HADS]--Anxiety and HADS-Depression; each scored 0-21). The primary end point was change in distress between consent and day 8. Secondary end points of distress, anxiety, and depression were assessed at defined intervals during follow-up. Optional, semistructured interviews occurring after completion of quantitative assessments were thematically analyzed. Results: Overall, 39 participants were enrolled in this study. The median time from orchidectomy to study consent was 14.8 (range 3-62) days. Moderate or high levels of distress evaluated using DT were reported in 58\% (23/39) of participants at consent and reduced to 13\% (5/38) after 1 week of observation. Early intervention with Nuts \& Bolts did not significantly decrease the mean DT score by day 8 compared with delayed intervention (early: 4.56-2.74 vs delayed: 4.47-2.74; P=.85), who did not yet have access to the website. A higher baseline DT score was significantly predictive of reduction in DT score during this period (P<.001). Median DT, HADS-Anxiety, and HADS-Depression scores reduced between orchidectomy and 3 weeks postoperatively and then remained stable throughout the observation period. Thematic analysis of 16 semistructured interviews revealed 4 key themes, ``Nuts \& Bolts is a helpful tool,'' ``Maximizing benefits of the website,'' ``Whirlwind of diagnosis and readiness for treatment,'' and ``Primary stressors and worries,'' as well as multiple subthemes. Conclusions: Distress is common following the diagnosis of testicular cancer; however, it decreases over time. Nuts \& Bolts was considered useful, acceptable, and relevant by individuals diagnosed with testicular cancer, with strong support for the intervention rendered by thematic analyses of semistructured interviews. The best time to introduce support, such as Nuts \& Bolts, is yet to be determined; however, it may be most beneficial as soon as testicular cancer is strongly suspected or diagnosed. ",
doi="10.2196/39725",
url="https://cancer.jmir.org/2022/4/e39725",
url="http://www.ncbi.nlm.nih.gov/pubmed/36306156"
}


@Article{info:doi/10.2196/42908,
author="Beuken, M. Maik J.
and Kanera, M. Iris
and Ezendam, Maria Nicole Paulina
and Braun, Susy
and Zoet, Martijn",
title="Identification and Potential Use of Clusters of Patients With Colorectal Cancer and Patients With Prostate Cancer in Clinical Practice: Explorative Mixed Methods Study",
journal="JMIR Cancer",
year="2022",
month="Dec",
day="27",
volume="8",
number="4",
pages="e42908",
keywords="colorectal cancer",
keywords="prostate cancer",
keywords="referral to aftercare",
keywords="patient clusters",
keywords="cluster analysis",
keywords="K-means cluster algorithm",
keywords="multiple-factor analysis",
keywords="expert panel group interviews",
keywords="interview",
keywords="cancer",
keywords="patient",
keywords="usability",
keywords="clinical",
keywords="colorectal",
keywords="recovery",
abstract="Background: A steady increase in colorectal and prostate cancer survivors and patients with these cancers is expected in the upcoming years. As a result of primary cancer treatments, patients have numerous additional complaints, increasing the need for cancer aftercare. However, referrals to appropriate cancer aftercare remain inadequate, despite a wide range of aftercare options. Caregivers and patients often do not know which aftercare is the most appropriate for the individual patient. Since characteristics and complaints of patients within a diagnosis group may differ, predefined patient clusters could provide substantive and efficient support for professionals in the conversation about aftercare. By using advanced data analysis methods, clusters of patients who are different from one another within a diagnosis group can be identified. Objective: This study had a 2-fold objective: (1) to identify, visualize, and describe potential patient clusters within the colorectal and prostate cancer population and (2) to explore the potential usability of these clusters in clinical practice. Methods: First, we used cross-sectional data from patients with colorectal cancer and patients with prostate cancer provided by the population-based PROFILES (Patient-Reported Outcomes Following Initial Treatment and Long-Term Evaluation of Survivorship) registry, which were originally collected between 2008 and 2012. To identify and visualize different clusters among the 2 patient populations, we conducted cluster analyses by applying the K-means algorithm and multiple-factor analyses. Second, in a qualitative study, we presented the patient clusters to patients with prostate, patients with colorectal cancer, and oncology professionals. To assess the usability of these clusters, we held expert panel group interviews. The interviews were video recorded and transcribed. Three researchers independently performed content-directed data analyses to understand and describe the qualitative data. Quotes illustrate the most important results. Results: We identified 3 patient clusters among colorectal cancer cases (n=3989) and 5 patient clusters among prostate cancer cases (n=696), which were described in tabular form. Patient experts (6/8, 75\%) and professional experts (17/20, 85\%) recognized the patient clustering based on distinguishing variables. However, the tabular form was evaluated as less applicable in clinical practice. Instead, the experts suggested the development of a conversation tool (eg, decision tree) to guide professionals through the hierarchy of variables. In addition, participants suggested that information about possible aftercare initiatives should be offered and integrated. This would also ensure a good overview and seemed to be a precondition for finding suitable aftercare. Conclusions: This study demonstrates that a fully data-driven approach can be used to identify distinguishable and recognizable (ie, in routine care) patient clusters in large data sets within cancer populations. Patient clusters can be a source of support for health professionals in the aftercare conversation. These clusters, when integrated into a smart digital conversation and referral tool, might be an opportunity to improve referral to cancer aftercare. Trial Registration: Netherlands Trial Register NL9226; https://trialsearch.who.int/Trial2.aspx?TrialID=NL9226 ",
doi="10.2196/42908",
url="https://cancer.jmir.org/2022/4/e42908",
url="http://www.ncbi.nlm.nih.gov/pubmed/36574281"
}


@Article{info:doi/10.2196/32153,
author="Nanton, Veronica
and Appleton, Rebecca
and Ahmed, Nisar
and Loew, Joelle
and Roscoe, Julia
and Muthuswamy, Radha
and Patel, Prashant
and Dale, Jeremy
and Ahmedzai, H. Sam",
title="A Web-Based Prostate Cancer--Specific Holistic Needs Assessment (CHAT-P): Multimethod Study From Concept to Clinical Practice",
journal="JMIR Cancer",
year="2022",
month="Oct",
day="19",
volume="8",
number="4",
pages="e32153",
keywords="Holistic Needs Assessment",
keywords="prostate cancer",
keywords="survivorship",
keywords="cancer follow-up",
keywords="coproduction",
keywords="web-based communication",
keywords="care planning",
abstract="Background: Men with prostate cancer experience immediate and long-term consequences of the disease and its treatment. They require both long-term monitoring for recurrence or progression and follow-up to identify and help manage psychosocial and physical impacts. Holistic Needs Assessment aims to ensure patient-centered continuing cancer care. However, paper-based generic tools have had limited uptake within cancer services, and there is little evidence of their impact. With the expansion of remote methods of care delivery and to enhance the value of generic tools, we developed a web-based Composite Holistic Needs Assessment Adaptive Tool-Prostate (CHAT-P) specifically for prostate cancer. Objective: This paper described the context, conceptual underpinning, and approach to design that informed the development of CHAT-P, starting from the initial concept to readiness for deployment. Through this narrative, we sought to contribute to the expanding body of knowledge regarding the coproduction process of innovative digital systems with potential for enhanced cancer care delivery. Methods: The development of CHAT-P was guided by the principles of coproduction. Men with prostate cancer and health care professionals contributed to each stage of the process. Testing was conducted iteratively over a 5-year period. An initial rapid review of patient-reported outcome measures identified candidate items for inclusion. These items were categorized and allocated to overarching domains. After the first round of user testing, further items were added, improvements were made to the adaptive branching system, and response categories were refined. A functioning version of CHAT-P was tested with 16 patients recruited from 3 outpatient clinics, with interviewers adopting the think-aloud technique. Interview transcripts were analyzed using a framework approach. Interviews and informal discussions with health care professionals informed the development of a linked care plan and clinician-facing platform, which were incorporated into a separate feasibility study of digitally enhanced integrated cancer care. Results: The findings from the interview study demonstrated the usability, acceptability, and potential value of CHAT-P. Men recognized the benefits of a personalized approach and the importance of a holistic understanding of their needs. Preparation for the consultation by the completion of CHAT-P was also recognized as empowering. The possible limitations identified were related to the importance of care teams responding to the issues selected in the assessment. The subsequent feasibility study highlighted the need for attention to men's psychological concerns and demonstrated the ability of CHAT-P to capture red flag symptoms requiring urgent investigation. Conclusions: CHAT-P offers an innovative means by which men can communicate their concerns to their health care teams before a physical or remote consultation. There is now a need for a full evaluation of the implementation process and outcomes where CHAT-P is introduced into the clinical pathway. There is also scope for adapting the CHAT-P model to other cancers. ",
doi="10.2196/32153",
url="https://cancer.jmir.org/2022/4/e32153",
url="http://www.ncbi.nlm.nih.gov/pubmed/36260380"
}


@Article{info:doi/10.2196/37272,
author="Acoba, D. Jared
and Yin, Chelsea
and Meno, Michael
and Abe, Justin
and Pagano, Ian
and Tamashiro, Sharon
and Fujinaga, Kristy
and Braun-Inglis, Christa
and Fukui, Jami",
title="Racial Disparities in Patient-Provider Communication During Telehealth Visits Versus Face-to-face Visits Among Asian and Native Hawaiian and Other Pacific Islander Patients With Cancer: Cross-sectional Analysis",
journal="JMIR Cancer",
year="2022",
month="Dec",
day="9",
volume="8",
number="4",
pages="e37272",
keywords="cancer",
keywords="telemedicine",
keywords="telehealth",
keywords="eHealth",
keywords="racial disparities",
keywords="race",
keywords="racial",
keywords="Asia",
keywords="Asian",
keywords="Hawaii",
keywords="Hawaiian",
keywords="Native Hawaiian",
keywords="Pacific Islander",
keywords="cross-sectional",
keywords="satisfaction",
keywords="oncology",
keywords="racially diverse",
keywords="patient-physician communication",
abstract="Background: Telehealth visits increase patients' access to care and are often rated as ``just as good'' as face-to-face visits by oncology patients. Telehealth visits have become increasingly more common in the care of patients with cancer since the advent of the COVID-19 pandemic. Asians and Pacific Islanders are two of the fastest growing racial groups in the United States, but there are few studies assessing patient satisfaction with telemedicine among these two racial groups. Objective: Our objective was to compare satisfaction with communication during telehealth visits versus face-to-face visits among oncology patients, with a specific focus on Asian patients and Native Hawaiian and other Pacific Islander (NHOPI) patients. Methods: We surveyed a racially diverse group of patients who were treated at community cancer centers in Hawaii and had recently experienced a face-to-face visit or telehealth visit. Questions for assessing satisfaction with patient-physician communication were adapted from a previously published study of cancer survivors. Variables that impact communication, including age, sex, household income, education level, and cancer type and stage, were captured. Multivariable logistic models for patient satisfaction were created, with adjustments for sociodemographic factors. Results: Participants who attended a face-to-face visit reported higher levels of satisfaction in all communication measures than those reported by participants who underwent a telehealth encounter. The univariate analysis revealed lower levels of satisfaction during telehealth visits among Asian participants and NHOPI participants compared to those among White participants for all measures of communication (eg, when asked to what degree ``[y]our physician listened carefully to you''). Asian patients and NHOPI patients were significantly less likely than White patients to strongly agree with the statement (P<.004 and P<.007, respectively). Racial differences in satisfaction with communication persisted in the multivariate analysis even after adjusting for sociodemographic factors. There were no significant racial differences in communication during face-to-face visits. Conclusions: Asian patients and NHOPI patients were significantly less content with patient-physician communication during telehealth visits when compared to White patients. This difference among racial groups was not seen in face-to-face visits. The observation that telehealth increases racial disparities in health care satisfaction should prompt further exploration. ",
doi="10.2196/37272",
url="https://cancer.jmir.org/2022/4/e37272",
url="http://www.ncbi.nlm.nih.gov/pubmed/36485021"
}


@Article{info:doi/10.2196/39228,
author="Huberty, Jennifer
and Bhuiyan, Nishat
and Puzia, Megan
and Joeman, Lynda
and Larkey, Linda
and Mesa, Ruben",
title="Meditation Mobile App Developed for Patients With and Survivors of Cancer: Feasibility Randomized Controlled Trial",
journal="JMIR Cancer",
year="2022",
month="Nov",
day="23",
volume="8",
number="4",
pages="e39228",
keywords="cancer",
keywords="mobile health",
keywords="mHealth",
keywords="meditation",
keywords="feasibility",
keywords="mobile phone",
abstract="Background: To address the unmet need for a commercial cancer-specific meditation app, we leveraged a long-standing partnership with a consumer-based app (ie, Calm) to develop the first commercial meditation app prototype adapted specifically for the needs of patients with cancer. Input was obtained at both the individual user and clinic levels (ie, patients with and survivors of cancer and health care providers). Objective: This study aimed to determine the feasibility of a cancer-specific meditation app prototype. Methods: Patients with and survivors of cancer who were recruited and enrolled in the feasibility randomized controlled trial were asked to use the prototype app daily (?70 minutes per week) for 4 weeks. Participants completed web-based weekly questionnaires and a final poststudy questionnaire and were asked to participate in an optional web-based poststudy interview. The questionnaires and interviews covered the following feasibility categories: acceptability, demand, practicality, and adaptation. Results: A total of 36 patients with and survivors of cancer completed the baseline questionnaire, 18 completed the final questionnaire, and 6 completed the optional interviews. Weekly and poststudy questionnaires indicated high overall enjoyment, ease of use, and satisfaction with the app content, aesthetics, and graphics. The objective use data indicated that the average total app use rate was 73.39 (SD 7.12) minutes per week. Interviews (N=6) revealed positive and mixed responses to the app prototype and informative differences related to preferences for narrators, emotional content, and meditation teaching but an overall appreciation for the variety of options. Conclusions: The most likely candidates for moving from cancer-specific meditation apps to dissemination are through partnering with the industry, in which name recognition and market distribution are already established (even showing a base of users from the targeted population with cancer). This study established the feasibility of a cancer-specific mobile meditation app prototype for patients with and survivors of cancer, using a commercially available app. The quantitative and qualitative data demonstrated the acceptability, demand, practicality, and adaptation of the prototype. Improvements suggested by the participants will be considered in the final app design before testing the efficacy of the app in a future study. Trial Registration: Clinicaltrials.gov NCT05459168; https://clinicaltrials.gov/ct2/show/record/NCT05459168 ",
doi="10.2196/39228",
url="https://cancer.jmir.org/2022/4/e39228",
url="http://www.ncbi.nlm.nih.gov/pubmed/36416880"
}


@Article{info:doi/10.2196/35310,
author="Valvi, Nimish
and Patel, Hetvee
and Bakoyannis, Giorgos
and Haggstrom, A. David
and Mohanty, Sanjay
and Dixon, E. Brian",
title="COVID-19 Diagnosis and Risk of Death Among Adults With Cancer in Indiana: Retrospective Cohort Study",
journal="JMIR Cancer",
year="2022",
month="Oct",
day="6",
volume="8",
number="4",
pages="e35310",
keywords="COVID-19",
keywords="SARS-CoV-2",
keywords="coronavirus",
keywords="cancer",
keywords="survival",
keywords="mortality",
keywords="death",
keywords="oncology",
keywords="cancer experience",
keywords="outcome",
keywords="electronic health record",
keywords="EHR",
keywords="patient with cancer",
keywords="cancer population",
keywords="Kaplan-Meier",
keywords="Cox proportional hazards model",
keywords="hazard ratio",
keywords="risk",
abstract="Background: Prior studies, generally conducted at single centers with small sample sizes, found that individuals with cancer experience more severe outcomes due to COVID-19, caused by SARS-CoV-2 infection. Although early examinations revealed greater risk of severe outcomes for patients with cancer, the magnitude of the increased risk remains unclear. Furthermore, prior studies were not typically performed using population-level data, especially those in the United States. Given robust prevention measures (eg, vaccines) are available for populations, examining the increased risk of patients with cancer due to SARS-CoV-2 infection using robust population-level analyses of electronic medical records is warranted. Objective: The aim of this paper is to evaluate the association between SARS-CoV-2 infection and all-cause mortality among recently diagnosed adults with cancer. Methods: We conducted a retrospective cohort study of newly diagnosed adults with cancer between January 1, 2019, and December 31, 2020, using electronic health records linked to a statewide SARS-CoV-2 testing database. The primary outcome was all-cause mortality. We used the Kaplan-Meier estimator to estimate survival during the COVID-19 period (January 15, 2020, to December 31, 2020). We further modeled SARS-CoV-2 infection as a time-dependent exposure (immortal time bias) in a multivariable Cox proportional hazards model adjusting for clinical and demographic variables to estimate the hazard ratios (HRs) among newly diagnosed adults with cancer. Sensitivity analyses were conducted using the above methods among individuals with cancer-staging information. Results: During the study period, 41,924 adults were identified with newly diagnosed cancer, of which 2894 (6.9\%) tested positive for SARS-CoV-2. The population consisted of White (n=32,867, 78.4\%), Black (n=2671, 6.4\%), Hispanic (n=832, 2.0\%), and other (n=5554, 13.2\%) racial backgrounds, with both male (n=21,354, 50.9\%) and female (n=20,570, 49.1\%) individuals. In the COVID-19 period analysis, after adjusting for age, sex, race or ethnicity, comorbidities, cancer type, and region, the risk of death increased by 91\% (adjusted HR 1.91; 95\% CI 1.76-2.09) compared to the pre--COVID-19 period (January 1, 2019, to January 14, 2020) after adjusting for other covariates. In the adjusted time-dependent analysis, SARS-CoV-2 infection was associated with an increase in all-cause mortality (adjusted HR 6.91; 95\% CI 6.06-7.89). Mortality increased 2.5 times among adults aged 65 years and older (adjusted HR 2.74; 95\% CI 2.26-3.31) compared to adults 18-44 years old, among male (adjusted HR 1.23; 95\% CI 1.14-1.32) compared to female individuals, and those with ?2 chronic conditions (adjusted HR 2.12; 95\% CI 1.94-2.31) compared to those with no comorbidities. Risk of mortality was 9\% higher in the rural population (adjusted HR 1.09; 95\% CI 1.01-1.18) compared to adult urban residents. Conclusions: The findings highlight increased risk of death is associated with SARS-CoV-2 infection among patients with a recent diagnosis of cancer. Elevated risk underscores the importance of adhering to social distancing, mask adherence, vaccination, and regular testing among the adult cancer population. ",
doi="10.2196/35310",
url="https://cancer.jmir.org/2022/4/e35310",
url="http://www.ncbi.nlm.nih.gov/pubmed/36201388"
}


@Article{info:doi/10.2196/42245,
author="Basch, H. Corey
and Hillyer, C. Grace
and Yalamanchili, Bhavya
and Morris, Aldean",
title="How TikTok Is Being Used to Help Individuals Cope With Breast Cancer: Cross-sectional Content Analysis",
journal="JMIR Cancer",
year="2022",
month="Dec",
day="6",
volume="8",
number="4",
pages="e42245",
keywords="TikTok",
keywords="breast cancer",
keywords="social media",
keywords="short video apps",
keywords="social support",
keywords="content analysis",
keywords="video",
keywords="patient support",
keywords="medical information",
keywords="health information",
keywords="peer support",
keywords="online conversation",
keywords="online health information",
abstract="Background: Acknowledging the popularity of TikTok, how quickly medical information can spread, and how users seek support on social media, there is a clear lack of research on breast cancer conversations on TikTok. There is a paucity of information on how these videos can advocate for those impacted by breast cancer as a means to provide support and information as well as raise awareness. Objective: The purpose of this cross-sectional content analysis was to describe the content of videos from the hashtag \#breastcancer on TikTok. Content related to breast cancer support and coping, cancer education, and heightening the awareness of breast cancer early detection, prevention, and treatment was evaluated. Methods: This study included 100 of the most viewed TikTok videos related to breast cancer through June 30, 2022. Videos were excluded if they were not in the English language or relevant to the topic being studied. Content was deductively coded into categories related to video characteristics and content topics using a screener based on expert breast cancer information sheets. Univariable analyses were conducted to evaluate differences in video characteristics and content when stratified as advocating or not advocating for breast cancer (yes or no) support, education, and awareness. Results: The cumulative number of views of the videos included in this study was 369,504,590. The majority (n=81, 81\%) of videos were created by patients and loved ones of individuals with breast cancer, and the most commonly discussed topic was breast cancer support (n=88, 88\%), followed by coping with the myriad issues surrounding breast cancer (n=79, 79\%). Overall, <50\% of the videos addressed important issues such as body image (n=48, 48\%), surgery (n=46, 46\%), medication and therapy (n=41, 41\%), or the stigma associated with a breast cancer diagnosis (n=44, 44\%); however, in videos that were advocacy oriented, body image (40/62, 64\% vs 8/38, 21\%; P<.001), stigma associated with breast cancer (33/62, 53\% vs 11/38, 29\%; P=.02), and breast cancer surgery (36/62, 58\% vs 10/38, 26\%; P=.002) were discussed significantly more often than in videos that did not specifically advocate for breast cancer. Conclusions: The use of videos to display health journeys can facilitate engagement by patients, family members, and loved ones interested in information about challenging conditions. Collectively, these findings highlight the level of peer-to-peer involvement on TikTok and may provide insights for designing breast cancer educational campaigns. ",
doi="10.2196/42245",
url="https://cancer.jmir.org/2022/4/e42245",
url="http://www.ncbi.nlm.nih.gov/pubmed/36472899"
}


@Article{info:doi/10.2196/43856,
author="Nanton, Veronica
and Appleton, Rebecca
and Ahmed, Nisar
and Loew, Joelle
and Roscoe, Julia
and Muthuswamy, Radha
and Patel, Prashant
and Dale, Jeremy
and Ahmedzai, H. Sam",
title="Correction: A Web-Based Prostate Cancer--Specific Holistic Needs Assessment (CHAT-P): Multimethod Study From Concept to Clinical Practice",
journal="JMIR Cancer",
year="2022",
month="Nov",
day="1",
volume="8",
number="4",
pages="e43856",
doi="10.2196/43856",
url="https://cancer.jmir.org/2022/4/e43856",
url="http://www.ncbi.nlm.nih.gov/pubmed/36318763"
}